Best Practices for Incorporating LAIs into Treatment Planning for Schizophrenia

Schizophrenia is an all-too-often chronic, debilitating disorder that impedes quality of life and psychosocial functioning. Implementation of effective therapy that promotes sustained recovery often poses a challenge for both clinicians and patients. Long-acting injectables (LAIs) can play a critical role in relapse prevention and rehospitalization, and subsequently, recovery and restoration of function.

This CME Outfitters BriefCase will guide clinicians through best practices to identify patients with schizophrenia who are ideal candidates for LAIs as well as effective communication strategies to facilitate the discussion of using LAIs in these patients.

- Learning Objectives -

At the end of this CE activity, participants should be able to:
- Identify patients with schizophrenia who are ideal candidates for LAI therapies and strategies for transitioning from oral therapies.

The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify patients with schizophrenia who are ideal candidates for LAI therapies and strategies for transitioning from oral therapies.